223 related articles for article (PubMed ID: 22474590)
1. 18-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in the Management of Aggressive Non-Hodgkin's B-Cell Lymphoma.
Shelly MJ; McDermott S; O'Connor OJ; Blake MA
ISRN Hematol; 2012; 2012():456706. PubMed ID: 22474590
[TBL] [Abstract][Full Text] [Related]
2. Different roles of surveillance positron emission tomography according to the histologic subtype of non-Hodgkin's lymphoma.
Kim YR; Kim SJ; Cheong JW; Kim Y; Jang JE; Cho H; Chung H; Min YH; Yang WI; Cho A; Kim JS
Korean J Intern Med; 2021 Mar; 36(Suppl 1):S245-S252. PubMed ID: 32550718
[TBL] [Abstract][Full Text] [Related]
3. Frequent impact of [18F]fluorodeoxyglucose positron emission tomography on the staging and management of patients with indolent non-Hodgkin's lymphoma.
Blum RH; Seymour JF; Wirth A; MacManus M; Hicks RJ
Clin Lymphoma; 2003 Jun; 4(1):43-9. PubMed ID: 12837154
[TBL] [Abstract][Full Text] [Related]
4. Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging.
Jerusalem G; Beguin Y; Fassotte MF; Najjar F; Paulus P; Rigo P; Fillet G
Blood; 1999 Jul; 94(2):429-33. PubMed ID: 10397709
[TBL] [Abstract][Full Text] [Related]
5. Use of FDG PET/CT in identification of bone marrow involvement in diffuse large B cell lymphoma and follicular lymphoma: comparison with iliac crest bone marrow biopsy.
Teagle AR; Barton H; Charles-Edwards E; Dizdarevic S; Chevassut T
Acta Radiol; 2017 Dec; 58(12):1476-1484. PubMed ID: 28382828
[TBL] [Abstract][Full Text] [Related]
6. Overview of the clinical effectiveness of positron emission tomography imaging in selected cancers.
Facey K; Bradbury I; Laking G; Payne E
Health Technol Assess; 2007 Oct; 11(44):iii-iv, xi-267. PubMed ID: 17999839
[TBL] [Abstract][Full Text] [Related]
7. High SUV uptake on FDG-PET/CT predicts for an aggressive B-cell lymphoma in a prospective study of primary FDG-PET/CT staging in lymphoma.
Ngeow JYY; Quek RHH; Ng DCE; Hee SW; Tao M; Lim LC; Tan YH; Lim ST
Ann Oncol; 2009 Sep; 20(9):1543-1547. PubMed ID: 19474116
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of diffuse large B-cell lymphoma patients with 64-slice multidetector computed tomography versus
Gómez León N; Vega G; Rodríguez-Vigil Junco B; Suevos Ballesteros C
Med Clin (Barc); 2018 Oct; 151(7):255-264. PubMed ID: 29705152
[TBL] [Abstract][Full Text] [Related]
9. Utero-Ovarian Involvement in Non-Hodgkin's Lymphoma on 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography: A Case Series and Literature Review.
Saini VK; Mammoottil AE; Nazar AH; Pavecha P; Ora M; Gambhir S
Indian J Nucl Med; 2022; 37(1):64-67. PubMed ID: 35478691
[TBL] [Abstract][Full Text] [Related]
10. Utilization of 18F-FDG PET/CT as a staging tool in patients with newly diagnosed lymphoma.
Cho SF; Chang CC; Liu YC; Chang CS; Hsiao HH; Liu TC; Huang CT; Lin SF
Kaohsiung J Med Sci; 2015 Mar; 31(3):130-7. PubMed ID: 25744235
[TBL] [Abstract][Full Text] [Related]
11. The role of 18F-FDG PET and 18F-FDG PET/CT in the evaluation of pediatric Hodgkin's lymphoma and non-Hodgkin's lymphoma.
Qiu L; Chen Y; Wu J
Hell J Nucl Med; 2013; 16(3):230-6. PubMed ID: 24137577
[TBL] [Abstract][Full Text] [Related]
12. [The role of PET/CT investigation in the management of patients with diffuse large B-cell lymphoma].
Paksi M; Demeter J; Szabó P
Magy Onkol; 2016 Jun; 60(2):108-17. PubMed ID: 27275637
[TBL] [Abstract][Full Text] [Related]
13. [Role of FDG-PET/CT in diffuse large B-cell lymphoma].
Masamoto Y; Kurokawa M
Rinsho Ketsueki; 2021; 62(9):1359-1366. PubMed ID: 34615795
[TBL] [Abstract][Full Text] [Related]
14. Promising Role of Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Human Immunodeficiency Virus Associated Non-Hodgkin's Lymphoma.
Kung BT; Mak WS; Lau SM; Auyong TK; Tong CM
World J Nucl Med; 2015; 14(1):53-6. PubMed ID: 25709547
[TBL] [Abstract][Full Text] [Related]
15. Discrepancies and priorities in staging and restaging malignant lymphoma by SPET, SPET/CT, PET/CT and PET/MRI.
Chavdarova LI; Tzonevska AD; Piperkova EN
Hell J Nucl Med; 2013; 16(3):223-9. PubMed ID: 24137584
[TBL] [Abstract][Full Text] [Related]
16. FDG-PET/CT in lymphoma.
Juweid ME
Methods Mol Biol; 2011; 727():1-19. PubMed ID: 21331925
[TBL] [Abstract][Full Text] [Related]
17. Isolated Splenic Tuberculosis Masquerading as Disease Progression of Hodgkin's Lymphoma on Interim
Dey S; Gupta N; Verma R; Seniaray N; Belho ES; Dhawan S
Indian J Nucl Med; 2021; 36(1):100-102. PubMed ID: 34040315
[No Abstract] [Full Text] [Related]
18. Lactate dehydrogenase levels and 18F-FDG PET/CT metrics differentiate between mediastinal Hodgkin's lymphoma and primary mediastinal B-cell lymphoma.
Alkhawtani RHM; Noordzij W; Glaudemans AWJM; van Rijn RS; van der Galiën HT; Balink H; Nijland M; Adams HJA; Huls G; van Meerten T; Kwee TC
Nucl Med Commun; 2018 Jun; 39(6):572-578. PubMed ID: 29672465
[TBL] [Abstract][Full Text] [Related]
19. PET imaging in pediatric Hodgkin's lymphoma.
Hudson MM; Krasin MJ; Kaste SC
Pediatr Radiol; 2004 Mar; 34(3):190-8. PubMed ID: 14745528
[TBL] [Abstract][Full Text] [Related]
20. Positron emission tomography/computed tomography in the management of Hodgkin's disease and non-Hodgkin's lymphoma.
Rodríguez-Vigil B; Gómez-León N; Pinilla I; Hernández-Maraver D; Coya J; Martín-Curto L
Curr Probl Diagn Radiol; 2006; 35(4):151-63. PubMed ID: 16814002
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
